Bijal Shah, MD, MS [slides]- CART Cell Therapy for Refractory ALL

Bijal Shah MD, MS, underscores the favorable outcomes of CAR T cell therapy for patients with relapsed refractory acute lymphoblastic leukemia (ALL), particularly those with extensive relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially Blinatumomab.

MD-Education Photo

MD-Education
3 months 19 Views
CART T-cell 10
Bijal Shah 3
MD-Education 73
AML-ALL US Focus Meeting 2023 72
Blinatumomab 15
blina 2
Inotuzumab 12
Gemtuzumab Ozogamicin 5
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
0
0
Category:
Acute Lymphoblastic Leukemia
Description:

Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center

Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know).

REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US - Online content available - https://aml-allus2023.md-education.com/register/
AML-ALL EU - Registration open - https://aml-alleu2023.md-education.com/register/
MPN-MDS EU - registration open - https://mpn-mdseu2023.md-education.com/register/

Bijal Shah MD, MS, compares CAR T therapy as a single agent to other immunotherapy approaches and stresses that the combination of these therapies can be transformative, akin to a seat belt and airbag working together for safety. They discuss the data demonstrating improved survival rates with CAR T cells, particularly for patients who had previously failed Blina and I know treatment. They also address challenges related to intercurrent infections and eligibility for CAR T treatment, emphasizing the need for earlier integration of CAR T therapy in the treatment pathway.